GW Pharmaceuticals

The race for a novel coronavirus vaccine has lit a fuse under biotech and pharmaceutical companies. 2020 will surely be remembered as the year of COVID-19 and an unprecedented boom for these industries. During good times, pharma stocks are attractive because of their steady cash flow, high-profit...

Less than a week after its most recent update on GW Pharmaceuticals plc (NASDAQ: GWPH), Cantor Fitzgerald lowered its price target for the stock Monday after the issuance of the company's 10-K report.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW...

GW Pharmaceuticals plc (NASDAQ: GWPH) Epidiolex drug and earlier-stage programs Sativex and CBDV will represent major catalysts for the stock in the near-term, in Cantor Fitzgerald's view.  The Analyst Analyst Elemer Piros reiterated an Overweight on GW Pharmaceuticals with a $211 price...

Benzinga has featured a look at many investor favorite stocks over the past week. Some recent posts took a look back at the past year. Many others were forward focused, including forecasts for the top tech darling. The end of the year is nearly upon us. As it does every week, Benzinga...

Elemer Piros of Cantor Fitzgerald maintained an Overweight rating and $208 price target on GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) after the developer of cannbinoid products reported its fiscal second-quarter results. Piros' main takeaway from the report and conference call is that GW...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), a developer of cannabinoid prescription medicines, spiked by more than 10 percent Monday morning following the company's announcement that Epidiolex achieved a primary endpoint in a Phase 3 clinical study. Epidiolex, GW Pharma's lead...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) soared Wednesday from around $83 per share to close at $104.03 after Reuters reported the company is in talks with an investment banks to consider strategic alternatives. GW Pharmaceuticals is a developer of marijuana-based epilepsy...

Shares of GW Pharmaceuticals PLC - ADR (NASDAQ: GWPH) spiked higher by more than 5 percent early Thursday morning after the company reported that data from a physician-led study into Epidiolex "reduced seizure frequency" across multiple drug-resistant epilepsy syndromes and seizure types and was "...